A 2019 finding indicated that the US regulatory process was slower than European standards.
3 reports, 3 independent
Updated Sep 10
Gone quiet
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A 2019 finding indicated that the US regulatory process was slower than European standards.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.State pressures and MFN policies are impacting the FDA's review process and US-EU market linkage.1 source
US FDA process was slower than European standards (2019 finding).1 source
Keep exploring
The entities involved
Related events
- FDA rule changes are causing delays in product approval, leading to the process exceeding Congressional mandated timeframes.
- MDR/IVDR reforms require adoption by the European Parliament, referencing US FDA pre-submission meetings.
- The FDA operates under US law to evaluate international clinical data.
- FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
- Industry trends are influenced by regulatory body requests, according to a recent report involving RTI International.